Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

536

HTML

4363

Figures (1-3)

355

Tables (1-3)

309

Sum=5563

Dec 6, 2012 (publication date) through Dec 25, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireview

World J Nephrol. Dec 6, 2012; 1(6): 184-194
Published online Dec 6, 2012. doi: 10.5527/wjn.v1.i6.184

Table 2 Cardiovascular risk factors in chronic kidney disease patients

Traditionals (Framingham-like)	Non-traditionals uremia-related
Age	Anemia
Male gender	Hyperomocysteinemia
Diabetes	Chronic inflammation
Obesity	Oxidative stress
Hypertension	Hyperparathyroidism and vascular calcifications
Smoking	Hyperparathyroidism and vascular calcifications
Insulin levels	Accumulation of metabolic products (advanced glycation end-products, asymmetric dimethyl arginine…)?
Family history
Dyslipidemia
↑ Total cholesterol
↑ LDL
↑ Apolipoprotein a1
↑ TG
↑ Apolipoprotein B
↓ HDL
↑ Lipoprotein (a)
↑ Oxidized LDL

HDL: High density lipoprotein; LDL: Low density lipoprotein; TG: Triglycerides.

Citation: Scarpioni R, Ricardi M, Albertazzi V, Melfa L. Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World J Nephrol 2012; 1(6): 184-194
URL: https://www.wjgnet.com/2220-6124/full/v1/i6/184.htm
DOI: https://dx.doi.org/10.5527/wjn.v1.i6.184